NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 69 filers reported holding NURIX THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $474,984 | -14.9% | 43,259 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $558,000 | +1.8% | 43,259 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $548,000 | -38.0% | 43,259 | -31.5% | 0.00% | 0.0% |
| Q1 2022 | $884,000 | -66.0% | 63,131 | -29.6% | 0.00% | -50.0% |
| Q4 2021 | $2,598,000 | +25.8% | 89,737 | +30.1% | 0.00% | 0.0% |
| Q3 2021 | $2,066,000 | -2.5% | 68,962 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $2,120,000 | -0.2% | 68,962 | +0.9% | 0.00% | 0.0% |
| Q1 2021 | $2,125,000 | +70.3% | 68,342 | +80.1% | 0.00% | 0.0% |
| Q4 2020 | $1,248,000 | -5.8% | 37,944 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $1,325,000 | – | 37,944 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |